KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Pacira BioSciences (PCRX) over the last 15 years, with Q3 2025 value amounting to $4.8 million.

  • Pacira BioSciences' Treasury Shares rose 46981.43% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 46981.43%. This contributed to the annual value of $837240.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Pacira BioSciences' Treasury Shares stood at $125.5 million, which was up 39975.32% from $75.5 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Treasury Shares registered a high of $4.8 million during Q3 2025, and its lowest value of $837000.0 during Q2 2024.
  • For the 5-year period, Pacira BioSciences' Treasury Shares averaged around $1.4 million, with its median value being $981953.0 (2022).
  • The largest annual percentage gain for Pacira BioSciences' Treasury Shares in the last 5 years was 39975.32% (2025), contrasted with its biggest fall of 20060.51% (2025).
  • Quarter analysis of 2 years shows Pacira BioSciences' Treasury Shares stood at $25.1 million in 2024, then surged by 399.75% to $125.5 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $2.8 million for Q2 2025, and $837000.0 during Q1 2025.